¶ Mild atopic dermatitis – Areas of dry skin, infrequent itching (with or without small areas of redness); little impact on everyday activities, sleep, and psychosocial wellbeing. Δ Moderate atopic dermatitis – Areas of dry skin, frequent itching, redness (with or without excoriation and localized skin thickening); moderate impact on everyday activities and psychosocial wellbeing, frequently disturbed sleep. ◊ Severe atopic dermatitis – Widespread areas of dry skin, incessant itching, redness (with or without excoriation, extensive skin thickening, bleeding, oozing, cracking, and alteration of pigmentation); severe limitation of everyday activities and psychosocial functioning, nightly loss of sleep. § Crisaborole is approved for mild to moderate atopic dermatitis in adults and children >3 months. ¥ TCIs are approved for mild to moderate atopic dermatitis in adults and children >2 years. TCIs include tacrolimus and pimecrolimus. ‡ Dupilumab is approved for moderate to severe atopic dermatitis in adults and children ≥12 years whose disease is not adequately controlled with topical prescription therapies.
